




RealRate

PHARMACEUTICAL 2022

Entasis Therapeutics Holdings Inc
Rank 325 of 471



RealRate

The First AI Rating Agency

www.realrate.ai

The relative strengths and weaknesses of Entasis Therapeutics Holdings Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Entasis Therapeutics Holdings Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 58% points. The greatest weakness of Entasis Therapeutics Holdings Inc is the variable Comprehensive Net Income, reducing the Economic Capital Ratio by 76% points.

The company's Economic Capital Ratio, given in the ranking table, is 216%, being 59% points below the market average of 275%.

Input Variable	Value in 1000 USD
Assets, Current	39,815
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	9,708
Liabilities, Non-Current	0
Other Assets	907
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	0
Other Net Income	0
Other Revenues	5,176
Property and Equipment	198
Research and Development	37,105
Selling, General and Administrative Expense	15,212

Output Variable	Value in 1000 USD
Assets	40,920
Liabilities	9,708
Expenses	52,317
Revenues	5,176
Stockholders Equity	31,212
Net Income	-47,141
Comprehensive Net Income	-47,141
BaseVar	54,060
ECR before Limited Liability	83%
Economic Capital Ratio	216%